Navigation Links
Cellectricon Files Patent Infringement Suit Against Fluxion Biosciences
Date:2/1/2010

GOTHENBURG, Sweden, February 1 /PRNewswire/ -- Cellectricon AB today announced that it has resumed its litigation against Fluxion Biosciences, Inc. Cellectricon filed the lawsuit in July 2009 in the United States District Court for the Northern District of California alleging infringement of several United States patents issued or licensed to Cellectricon for microfluidic technology used in Cellectricon's state-of-the-art ion channel drug screening solution, the Dynaflow(R)HT System. Cellectricon's U.S. Patents Nos. 7,390,650, 7,470,518 and 7,563,614 have been asserted in the litigation, as well as U.S. Patent No. 5,376,252, which is owned by Gyros, and licensed to Cellectricon.

Annelie Skafte Persson, Cellectricon's Chief Executive Officer, said, "Cellectricon invents and develops advanced cell-based microfluidic screening solutions for applications in drug discovery and basic research. Cellectricon has an extensive intellectual property portfolio with novel cell-based screening technologies based on fifteen years of world-renowned research. To ensure a fair return on our research and development efforts we must protect our intellectual property and we will take all necessary steps to prevent its unauthorized use."

Cellectricon's Chairman Lars-Eric Utterman added, "Cellectricon is a highly innovative company which has successfully launched several advanced screening systems on the life science market. Today's litigation is a strategic step to defend Cellectricon's intellectual property from being infringed."

About Cellectricon

Cellectricon AB, a Swedish biotech company, successfully provides groundbreaking products to the pharmaceutical and biotechnology industries. The company utilizes state-of-the-art interfaces to biological systems by employing novel microfluidic technologies. This enables completely new types of assays and devices with superior performance characteristics and robustness. Cellectricon's products address critical bottlenecks in the drug discovery process and have been adopted by top-reference customers, including nine of the top ten pharmaceutical companies. Cellectricon has developed two pioneering high throughput screening platforms in close collaboration with leaders in the pharmaceutical industry. Used in preclinical pharmaceutical development, the Cellaxess(R)HT System enables high throughput transfection for genomic screening and the Dynaflow(R)HT System greatly advances ion channel drug discovery.

    Contact Details:

    Annelie Skafte Persson, CEO
    E-mail: annelie.skafte.persson@cellectricon.com

    Susanne Fagerlund, VP Marketing & Communications
    E-mail: susanne.fagerlund@cellectricon.com

SOURCE Cellectricon AB


'/>"/>
SOURCE Cellectricon AB
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Share Issue Gives Cellectricon SEK 89 Million to Continue its Rapid Market Expansion
2. Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology
3. Cellectricon Receives Milestone Order for Cellaxess(R)HT, the Worlds First High Throughput RNAi Screening System
4. Cellectricon Partners With The Automation Partnership - Bringing Next Generation Ion Channel Screening System to Market.
5. Cellectricon and BioFocus DPI Advance High Throughput ion Channel Drug Discovery
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
8. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
9. Arrow International Files and Mails Definitive Proxy Materials
10. VaxGen Files 2006 Financial Statements and Provides Cash Update
11. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... -- Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual property development ... property, today provided an update on the Company,s cases ... Texas and announcing that those ... Re-examination ("IPR") proceedings that VTech and Uniden filed ... on only certain claims of two of the patents ...
(Date:2/3/2016)... Feb. 3, 2016   ViaCyte, Inc ., ... first pluripotent stem cell-derived islet replacement therapy for ... development, today announced that ViaCyte and Janssen Biotech, ... Johnson & Johnson, have agreed to consolidate the ... The agreement provides ViaCyte with an exclusive license ...
(Date:2/3/2016)... , Feb. 3, 2016 New ... more than $1 million for researchers in ... on health-related research that demonstrates exciting potential.   ... of funding for the New Jersey Health Foundation Research ... members at these educational institutions— Princeton University, Rutgers ...
(Date:2/3/2016)... -- Silk Therapeutics, Inc., today announced the closing of a $6 ... a total of $10.25 million in Series A funding based ... round was led by existing investor The Kraft Group of ... investors Lear Corporation and Highland Consumer Partners, as well as ... Richard Sackler , MD, with Summer Road, LLC; Erin ...
Breaking Biology Technology:
(Date:2/3/2016)... , February 4, 2016 --> ... to SEK 1,351.5 M (105.0), up 1,187% compared with fourth quarter of ... amounted to SEK 517.6 M (loss: 30.0). Earnings per share ... activities was SEK 537.4 M (neg: 74.7). , ... , Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% compared with ...
(Date:2/2/2016)... YORK , Feb. 2, 2016 /PRNewswire/ ... facilities are primarily focused on medical screening ... measure point-of-care parameters. Wearable devices that facilitate ... user,s freedom of movement are being bolstered ... for human biomedical signal acquisition coupled with ...
(Date:2/2/2016)... 2016   Parabon NanoLabs (Parabon) announced ... Research Office and the Defense Forensics and Biometrics ... the company,s Snapshot Kinship Inference software ... generally, defense-related DNA forensics.  Although Snapshot is best ... and ancestry from DNA evidence), it also has ...
Breaking Biology News(10 mins):